Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: Results of the FAB/LMB 96 international study

Leukemia

Volumn 23, Issue 2, 2009, Pages 323-331

  Poirel, H A ^a,b   Cairo, M S ^c   Heerema, N A ^d   Swansbury, J ^e   Auperin A ^f   Launay, E ^a   Sanger, W G ^g   Talley, P ^h   Perkins, S L ⁱ   Raphael M ^a,j   McCarthy, K ^k   Sposto, R ^l   Gerrard, M ^h   Bernheim, A ^f   Patte, C ^f  

^a UNIVERSITÉ PARIS 13   (France)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^h SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j BICÊTRE HOSPITAL   (France)

^k GLOUCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^l UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CHILD; CHROMOSOME 13Q; CHROMOSOME 1Q; CHROMOSOME 7Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE DELETION; HUMAN; INCIDENCE; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 60149085845     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.312     Document Type: Article

References (37)

1. Patte C, Auperin A, Gerrard M, Michon J, Pinkerson CR, Sposto R et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin's lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. Blood 2007; 109: 2773-2780.
2. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerson CR, Michon J et al. Results of a randomized international study of high risk central nervous system B-non-Hodgkin's lymphoma and B-acute lymphoblastic leukemia in children and adolescents. Blood 2007; 109: 2736-2743.
3. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, Lambilliote A et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's Lymphoma: Results of the FAB/LMB 96 International Study. Br J Haematol 2008; 141: 840-847.
4. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
5. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumors. Pathology & Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 181-184.
6. Lenoir GM, Preud'homme JL, Bernheim A, Berger R. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma. Nature 1982; 298: 474-476.
7. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H et al. The human c-myc oncogene: Structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell 1983; 34: 779-787.
8. Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 1976; 17: 47-56.
9. Bernheim A, Berger R, Lenoir G. Cytogenetic studies on African Burkitt's lymphoma cell lines: T(8;14), t(2;8) and t(8;22) translocations. Cancer Genet Cytogenet 1981; 3: 307-315.
10. Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood 2004; 104: 3009-3020.
11. Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A et al. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia 2004; 18: 584-588.
12. Lindstrom MS, Wiman KG. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol 2002; 12: 381-387.
13. Berger R, Bernheim A. Cytogenetics of Burkitt's lymphoma-leukaemia: A review. IARC Sci Publ 1985; 60: 65-80.
14. Berger R, Le Coniat M, Derre J, Vecchione D. Secondary nonrandom chromosomal abnormalities of band 13q34 in Burkitt lymphoma-leukemia. Genes Chromosomes Cancer 1989; 1: 115-118.
15. Lai JL, Fenaux P, Zandecki M, Nelken B, Huart JJ, Deminatti M. Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet 1989; 32: 26-32.
16. Kornblau SM, Goodacre A, Cabanillas F. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature. Hematol Oncol 1991; 9 63-78.
17. Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood 1995; 86: 3905-3914.
18. Berger R, Bernheim A. Is there a functional equivalence between abnormalities of the long arm of chromosome 1 and the presence of Epstein-Barr virus in continuous lines of Burkitt's lymphoma? C R Acad Sci III 1984; 298: 143-145.
19. Knutsen T. Cytogenetic changes in the progression of lymphoma. Leuk Lymphoma 1998; 31: 1-19.
20. Garcia JL, Hernandez JM, Gutierrez NC, Flores T, Gonzalez D, Calasanz MJ et al. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia 2003; 17: 2016-2024.
21. Lones MA, Sanger WG, Le Beau MM, Heerema NA, Sposto R, Perkins SL, et al., Children's Cancer Group Study CCG-E08. Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: A report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol 2004; 26: 169-178.
22. Heerema NA, Bernheim A, Lim MS, Look AT, Pasqualucci L, Raetz E et al. State of the art and future needs in cytogenetic/molecular genetics/arrays in childhood lymphoma: Summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer 2005; 45: 616-622.
23. Dave BJ, Weisenburger DD, Higgins CM, Pickering DL, Hess MM, Chan WC et al. Cytogenetics and fluorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults. Cancer Genet Cytogenet 2004; 153: 115-121.
24. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: Highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001; 97: 3370-3379.
25. Lones MA, Auperin A, Raphael M, McCarthy K, Perkins SL, MacLennan KA et al. Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American lymphoma classification. Ann Oncol 2000; 11: 47-51.
26. Shaffer LG, Tommerup N (eds). An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S Karger: Basel, 2005.
27. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group trial NHL-BFM 90. Blood 1999; 94 3294-3306.
28. Barin C, Valtat C, Briault S, Bremont JL, Petit A, Lejars O et al. Structural rearrangements of chromosome 13 as additional abnormalities in Burkitt lymphoma and type 3 acute lymphoblastic leukemia. Cancer Genet Cytogenet 1992; 60: 206-209.
29. Ogden CA, Pound JD, Batth BK, Owens S, Johannessen I, Wood K et al. Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: Implications for Burkitt's lymphoma. J Immunol 2005; 174: 3015-3023.
30. Calin GA, Liu CG, Sevignani C, Ferracin M, Felli N, Dumitru CD et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004; 101: 11755-11760.
31. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF et al. Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419-2430.
32. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. Lymphoma/Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354: 2431-2442.
33. Kawasaki C, Ohshim K, Suzumiya J, Kanda M, Tsuchiya T, Tamura K et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma 2001; 42: 1099-1106.
34. Akasaka T, Akasaka H, Ueda C, Kanda M, Tsuchiya T, Tamura K et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000; 18: 510-518.
35. Miles R, Raphael M, McCarthy K, Wotherspoon A, Lones M, Cairo M et al. Diffuse large B-cell lymphomas in pediatric patients demonstrate a marked predominance of germinal center cell phenotype. Ann Oncol 2005 (abstract) 16: V 61.
36. Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: A clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107 4047-4052.
37. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.